---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-409865"
form_type: "8-K"
ticker: "EVMN"
cik: "0002044725"
company_name: "Evommune, Inc."
filed_at: "2026-10-01T12:01:58+00:00"
generated_at: "2026-10-12T14:16:03.553812+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Evommune's EVO301 hits Phase 2a primary endpoint in atopic dermatitis: 55% EASI reduction vs 22% placebo

## Summary
- Phase 2a trial (n=70; 48 active, 22 placebo) of IV EVO301 5mg/kg at Baseline and Week 4 met its primary endpoint: 55% LS mean EASI reduction at Week 12 vs 22% on placebo (p<0.01).
- EASI-50 at Week 12 was 63% for EVO301 vs 23% placebo; EASI-75 was 29% vs 9%; separation appeared by Week 4 (41% vs 18%) and held through Week 8 (50% vs 16%).
- Safety: no treatment-related serious or severe adverse events, no discontinuations, no conjunctivitis; treatment-related AEs in 10.4% of EVO301 patients vs 13.6% on placebo.
- Biomarkers: ~75% reduction in CCL-17 (TARC) in patients with high baseline TARC, with reductions also in CCL-22, IL-22 and Th1/Th17/Th22 pathway markers.
- Subcutaneous Phase 2b dose-ranging trial on track to begin mid-2027; PK profile supports Q4-week dosing with potential every-8-to-12-week maintenance.

## SEC filing metadata
- accession: 0001193125-26-409865
- form_type: 8-K
- ticker: EVMN
- cik: 0002044725
- company_name: Evommune, Inc.
- filed_at: 2026-10-01T12:01:58+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2044725/000119312526409865/0001193125-26-409865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2044725/000119312526409865/evmn-20261001.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-409865
- JSON: https://secwatch.observer/filing/0001193125-26-409865.json
- Plain text: https://secwatch.observer/filing/0001193125-26-409865.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.